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Aim: The JAK2 V617F mutation has been described as a frequent genetic event among a majority of patients with polycythemia vera,
essential thrombocythemia, and myelofibrosis. In this research, we evaluated the prevalence of the JAK2 mutation and its clinical and
laboratory correlation in patients with myeloproliferative neoplasms.
Materials and methods: A total of 615 patients with suspected myeloproliferative neoplasms (MPNs) were analyzed for the JAK2 V617F
mutation. After DNA extraction, detection of the mutation was done using allele-specific PCR. Positive samples were subsequently
analyzed with PCR-RFLP by the restriction endonuclease BsaXI. The patients were also analyzed for hematological indices.
Results: Of 615 patients, 175 (28.4%) patients were positive for the JAK2 V617F mutation, whereas 440 (71.6%) patients were negative.
The positive group included 79 (45.1%) patients with essential thrombocythemia, 62 (35.4%) patients with polycythemia vera, 27
(15.4%) patients with primary myelofibrosis, and 7 (4%) patients with unclassified MPNs.
Conclusion: The frequency of the JAK2 mutation in our study is compatible with previous reports. JAK2 V617F mutation screening
can be incorporated in the initial evaluation of patients suspected of having MPNs. The relationship between the JAK2 mutation and
hematological indices can be used in new diagnostic and therapeutic strategies.
Key words: JAK2, mutation, myeloproliferative neoplasms

1. Introduction
Myeloproliferative neoplasms (MPNs) are a group of
hematological neoplasms that share similar molecular
and cellular abnormalities. However, these diseases differ
in their phenotypes, clinical presentation, and therapy
(1–3). MPNs have been previously called MPDs, or
myeloproliferative disorders. However, according to the
World Health Organization (WHO) classification, MPN
is the most up-to-date term for these diseases (4). This
reflects the underlying clonal genetic changes that are a
salient feature of this group of diseases. According to the
WHO classification, MPNs are divided into 2 large groups:
those that possess the BCR-ABL1 fusion protein, such as
chronic myeloid leukemia (CML), and those that are BCRABL1–negative (5), including polycythemia vera (PV),
essential thrombocythemia (ET), myelofibrosis (MF),
* Correspondence: m.farshdousti@gmail.com

mastocytosis, chronic neutrophilic leukemia, and chronic
eosinophilic leukemia. The latter group of MPNs shares
elements of pathogenesis and symptomatology that may
be related to dysregulated Janus kinase (JAK) signaling
(2). The family of tyrosine kinases, termed Janus kinases
(JAKs), has a vital role in signal transduction in cells.
JAK2 is essential for the proliferation and differentiation
of erythroid and megakaryocytic lineages (6,7). JAK2
plays a role in downstream signaling pathways, such as
the JAK/signal transducer and activator of transcription
(STAT) pathway that is involved in cytokine signaling.
JAK2 possesses 7 defined regions of conserved homology,
denoted as JAK homology (JH) domains 1–7 (8). JH2 is a
pseudokinase domain that early functional studies show
has an inhibitory effect on the JAK2 kinase domain (9–
11).
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The clinical presentation and laboratory findings of
these diseases are variable, but common elements can
include splenomegaly, increased risk of thrombosis and/
or bleeding, overproduction of one or more of the myeloid
cell lines, bone marrow hypercellularity with or without
fibrosis, debilitating symptoms, and the potential to
progress to secondary acute myelogenous leukemia (12).
MPNs are relatively rare conditions. In the United States
there are about 95,000 patients with PV, about 80,000
patients with ET, and about 16,000 to 18,500 patients with
MF. These diseases usually affect older adults; the average
age of onset is 61 (13).
In 2005, 4 independent research groups identified a single acquired mutation in the JAK2 gene on chromosome 9
that had a high incidence of occurrence in patients with PV,
ET, or MF (14–17). The point mutation in exon 14 of JAK2
alters codon 617 from a valine to a phenylalanine. This amino acid alteration in the JH2 domain of JAK2 causes a constitutive activation of the tyrosine kinase, which is believed
to confer erythropoietin hypersensitivity and erythropoietin-independent survival to the myeloid stem cell (18). This
mutation is a gain of function mutation, in that it releases
the autoinhibitory action of JH2 and recruits STAT in the
complete absence, or in presence of only trace quantities, of
hematopoietic growth factors (19–21).
The detection of the JAK2 V617F mutation provides
a qualitative diagnostic parameter for the identification
of the nonchronic myelogenous leukemia subgroup of
MPNs. Different groups reported a variable frequency of
JAK2 V617F mutation ranging from 65%–97% for PV,
23%–57% percent for ET, and 35%–%57 percent for MF
(14,16,22,23). In this study, we evaluated the prevalence
of the JAK2 mutation and its clinical and laboratory
correlations in patients with MPNs.
2. Materials and methods
2.1. Patients
Included in this study were 615 patients with suspected
MPNs that were referred by physicians for JAK2 V617F
mutation analysis. The necessary investigations, including
measurements of white blood cell (WBC) count, red blood
cell (RBC) count, platelet (Plt) count, WBC differential
count, hemoglobin (Hb), hematocrit (Hct), and clinical
characteristics, were performed whenever required. Local
ethical approval for the study protocol was obtained, and
written informed consent was taken from all patients.
2.2. DNA extraction
We took a blood sample (10 mL) from every patient.
Granulocytes were separated from peripheral blood, and
genomic DNA was extracted using conventional phenol/
chloroform protocol after proteinase K digestion following
standard published protocols. DNA was quantified using
spectrophotometric measurements.
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2.3. Analysis of the JAK2 V617F mutation
All DNA samples were genotyped for the JAK2 V617F
mutation by an allele-specific (ASO) polymerase chain
reaction (PCR), exactly as described by Baxter et al. (14),
in which 1 μmol/L of a common reverse primer, 0.5 μmol/L
of a forward primer specific for the mutant allele (giving a
203-bp product), and 0.5 μmol/L of another forward primer
amplifying a 364-bp product from both mutant and wild
type alleles, which also serves as an internal PCR control,
were used. Samples that were positive for the mutation
were subsequently analyzed via PCR-restriction fragment
length polymorphism (PCR-RFLP) with the restriction
endonuclease BsaXI (New England Biolabs, Hitchin, UK),
which allows for estimation between mutated and wildtype alleles. Successful amplification was confirmed by
electrophoresis on an ethidium bromide-impregnated 2%
agarose gel. The G-T mutation destroys a BsaXI site present
in the wild-type JAK2 sequence. This approach allows
both normal and mutant alleles to be visualized and can
be distinguished between homozygous and heterozygous
mutations.
2.4. Statistical analysis
Comparison of clinical characteristics between cases
with and without JAK2 V617F mutation was done using
the Mann–Whitney U test (Wilcoxon rank sum test) for
WBC and Plt count, the t-test for age and Hb, and the chisquare test for sex, using SPSS 11. P < 0.05 was considered
statistically significant.
3. Results
The JAK2 V617F mutation was analyzed in 615 patients
with suspected MPNs that were referred by physicians for
JAK2 V617F mutation analysis. In this group, 175 (28.4%)
of the patients were positive for the JAK2 V617F mutation,
whereas 440 (71.6%) patients were negative for the JAK2
V617F mutation. The JAK2 V617F mutation-positive
group (175 patients) included 79 (45.1%) patients with
ET, 62 (35.4%) patients with PV, 27 (15.4%) patients with
primary myelofibrosis (PMF), and 7 (4%) patients with
unclassified MPNs. The JAK2 V617F mutation-negative
group (440 patients) included 94 (21.4%) patients with
ET, 61 (13.8%) patients with non-MPN polycythemia, 41
(9.3%) patients with MF, 4 (0.9%) patients with CML, 11
(2.5%) patients with thrombocytopenia, 3 (0.7%) patients
with hairy cell leukemia, and 226 (51.4%) normal referred
patients. Other patient characteristics, including the sex
and age of both positive and negative groups, are shown in
Table 1 and Table 2, respectively. The mean ages of JAK2
V617F-positive patients were 59.86 ± 14.53 years (range:
21–88) in males and 57.14 ± 16.08 years (range: 23–85) in
females, and those of the JAK2 V617F-negative patients
were 43.29 ± 17.74 years (range: 4–91) in males and 48.12
± 18.96 years (range: 6–82) in females.
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Table 1. Characteristics of patients with the JAK2 mutation.
Disease

Number of patients (%)

Male/female, n

Male mean age (range)

Female mean age (range)

ET

79 (45.1)

40/39

60.93 ± 14.48
(22–85)

57.28 ± 16.64
(23–80)

PV

62 (35.4)

31/31

58.82 ± 14.12
(28–88)

56.74 ± 14.64
(23–84)

PMF

27 (15.4)

18/9

61.39 ± 12.43
(38–85)

55.22 ± 18.95
(28–85)

7 (4)

6/1

55.17 ± 23.58
(21–84)

81

175 (100)

95/80

59.86 ± 14.53
(21–88)

57.14 ± 16.08
(23–85)

Unclassified MPNs
Total

Table 2. Characteristics of patients without the JAK2 mutation.
Disease

Number of patients (%)

Male/female, n

Female mean age (range)

Male mean age (range)

94 (21.4)

46/48

48.94 ± 18.93
(14–82)

48.54 ± 19.12
(11–89)

CML

4 (0.9)

1/3

58.33 ± 16.80
(40–73)

70

PMF

41 (9.3)

19/22

57.05 ± 14.03
(77–32)

64.26 ± 18.49
(19–91)

Polycythemia, non-MPN

61 (13.8)

49/12

34.75 ± 18.05
(16–65)

42.41 ± 16.96
(48–65)

Thrombocytopenia

11 (2.5)

6/5

48.4 ± 22.6
(30–76)

49.17 ± 9.75
(32–61)

Hairy cell leukemia

3 (0.7)

2/1

65

49.5 ± 0.71
(49–50)

Normal referred patients

226 (51.4)

171/55

45.85 ± 19.33
(6–81)

39.36 ± 15.72
(7–78)

Total

440 (100)

294/146

48.12 ± 18.96
(6–82)

43.29 ± 17.74
(4–91)

ET

Both positive and negative groups were analyzed for
hematological indexes, including WBC count, RBC count,
Plt count, WBC differentiation count, Hb, and Hct. The
overall presence of the JAK2 V617F mutation in the positive
group was associated with a higher WBC count (P < 0.01)
in JAK2-positive men than JAK2-negative men, whereas
there was no statistical difference in women. RBC count,
Hb, and Hct were higher in JAK2-positive women than
JAK2-negative women (P < 0.01), but RBC count, Hb, and
Hct did not differ in JAK2-positive and -negative men. Plt

count was higher in both JAK2-positive men and women
than in the negative group (P < 0.01). In a differential
WBC count, the neutrophil count was higher in both
JAK2-positive men and women than in the negative group
(P < 0.01). However, the lymphocyte count was lower in
both JAK2-positive men and women than in the negative
group (P < 0.01). Hematological indexes including WBC
count, RBC count, Plt count, WBC differentiation count,
Hb, and Hct in the positive and negative groups are shown
in Tables 3 and 4.
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Positive patients

Negative patients

11.69 ± 5.47
10.2
(5.8–43.8)

18.54 ± 18.36
12.6
(3.5–85.5)

13.21 ± 5.58
12.15
(4.7–29.4)

8.12 ± 2.41
7.5
(5.6–12.1)

11.48 ± 7.82
9.3
(4.3–49)

113.03 ± 36.33
112.9
(71–155)

15.51 ± 20.53
6.4
(1.2–95.4)

7.89 ± 3.04
7.2
(2.9–17.7)

10.52 ± 15.54
5.7
(2.1–56.3)

7.64 ± 2.81
7
(2.4–21)

ET
mean ± SD
Median
(range)

PMF
mean ± SD
Median
(range)

PV
mean ± SD
Median
(range)

MPN
mean ± SD
Median
(range)

ET
mean ± SD
Median
(range)

CML
mean ± SD
Median
(range)

PMF
mean ± SD
Median
(range)

Polycythemia non-MPN
mean ± SD
Median
(range)

Thrombocytopenia
mean ± SD
Median
(range)

Normal
mean ± SD
Median
(range)

WBC

5.53 ± 1.04
5.59
(0.5–15.54)

4.96 ± 0.78
4.61
(3.61–6.4)

6.74 ± 0.92
6.5
(5.55–9.27)

4.01 ± 1.01
3.97
(0.5–15.54)

3.99 ± 0.67
3.97
(3.3–4.73)

5.17 ± 1.75
4.82
(2.62–15.97)

5.43 ± 0.63
5.27
(4.63–6.42)

7.23 ± 1.15
6.95
(5.27–9.91)

4.41 ± 1.28
4.3
(2.14–7.72)

5.96 ± 3.74
5.57
(3.54–37.7)

RBC

15.81 ± 2.04
16.5
(7–23.9)

14.25 ± 2.32
14.1
(9.5–17.7)

18.82 ± 1.82
18.7
(9.5–23.3)

10.56 ± 1.97
10.4
(6.9–15.7)

10.78 ± 1.26
10.7
(9.6–12.1)

13.05 ± 2.3
13.35
(8.6–19.4)

15.3 ± 0.97
15.25
(13.7–16.6)

18.02 ± 1.48
17.8
(14.1–21.6)

11.99 ± 2.27
12.3
(5.5–15.6)

14.40 ± 1.64
14.3
(9.5–17.5)

HB

46.45 ± 4.73
47.7
(25.8–60.6)

41.84 ± 5.94
39.9
(32.6–51.3)

55.98 ± 4.37
54.9
(49.6–69.3)

33.16 ± 6.17
33
(22.1–52.5)

34.53 ± 3.5
33.75
(31.6–39)

43.75 ± 40.94
40.3
(24.4–432)

45.3 ± 1.11
45.8
(43.3–46.2)

54.59 ± 8.01
55.15
(2.9–65.8)

37.59 ± 6.45
37.8
(20–46.6)

44.02 ± 7.72
43.3
(2.3–19.2)

HCT

244.94 ± 98.18
223
(57–971)

58.55 ± 21.34
61
(19–96)

205.18 ± 74.14
213
(20–403)

233.51 ± 169.6
247
(25–663)

475 ± 417.86
391.5
(63–1054)

874.89 ± 370.26
776
(461–2350)

289.67 ± 87.64
261
(191–436)

515.82 ± 227.98
512.5
(151–1028)

296.63 ± 158.82
293
(44–677)

867.9 ± 332.58
803
(355–2571)

Plt

0.91 ± 0.60
1
(0–4)

1.8 ± 2.39
1
(0–6)

0.91 ± 0.53
1
(0–2)

2.5 ± 2.77
1
(0–11)

5 ± 6.08
2
(1–12)

1.34 ± 0.98
1
(0–5)

1.33 ± 0.58
1
(1–2)

1.46 ± 1.27
1
(0–6)

1.56 ± 0.81
1
(1–4)

1.41 ± 1.08
1
(0–7)

Basophils

Table 3. Hematological parameters in JAK2-positive and -negative patients.

3.89 ± 8.67
2
(0–88)

3.05 ± 2.22
3
(0–10)

3.21 ± 2.22
3
(0–10)

3.21 ± 2.83
2
(1–14)

3.5 ± 0.71
3.5
(3–4)

3.14 ± 2.03
3
(1–8)

2.75 ± 0.96
2.5
(2–4)

2.95 ± 2.07
3
(0–8)

3.27 ± 2.98
3
(1–15)

3.7 ± 1.97
3
(1–8)

Eosinophils

4.89 ± 2.25
5
(0–11)

4.16 ± 2.55
3.5
(0–11)

4.16 ± 2.55
3.5
(0–11)

6.63 ± 7.79
5
(1–40)

6 ± 4.25
6
(3–9)

4.96 ± 2.58
5
(1–15)

3.75 ± 1.89
4.5
(1–5)

3.02 ± 1.62
3
(0–7)

4.71 ± 6.18
3.5
(1–32)

3.83 ± 2.19
4
(0–8)

Monocytes

32.86 ± 10.91
32
(1–76)

34.82 ± 14.36
33.5
(3–93)

34.82 ± 14.36
33.5
(3–93)

21.35 ± 14.16
19
(5–59)

7.67 ± 1.53
8
(6–9)

26.45 ± 12.46
25
(1–52)

19 ± 7.62
16.5
(13–30)

17.10 ± 8.22
18
(2–40)

17.22 ± 10.89
14
(1–42)

20.57 ± 10.14
19
(4–48)

Lymphocytes
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Table 4. Comparison of hematological parameters between male and female patients with the JAK2 mutation. **: P < 0.01.
Male JAK2 V617F (+)

Male JAK2 V617F (-)

Female JAK2 V617F (+)

Female JAK2 V617F (–)

Age, mean ± SD
(range)

59.86 ± 14.53
(21–88)

43.29 ± 17.74
(4–91)

57.14 ± 16.08**
(23–85)

48.12 ± 18.96
(6–82)

WBC (×109/L),
mean ± SD
Median
(range)

13.51 ± 10.85**
10.5
(4.1–85.5)

9.15 ± 9.29
7.3
(2.1–128)

12-.77 ± 6.32
11.15
(3.5–39)

12.46 ± 18.65
7.85
(1.2–155)

RBC,
mean ± SD
Median
(range)

5.94 ± 1.56
5.89
(2.14–9.91)

5.69 ± 1.29
5.69
(0.5–15.97)

6.4 ± 3.8**
6.15
(3.01–37.7)

4.94 ± 1.42
4.72
(2.05–14.63)

HB (g/dL),
mean ± SD
Median
(range)

15.38 ± 2.97
15.65
(5.5–21.6)

15.92 ± 2.68
16.7
(6.9–21.2)

15.32 ± 2.47**
15.1
(9.7–21.1)

13.27 ± 3.058
13.3
(7.4–23.9)

HCT,
mean ± SD
Median
(range)

46.52 ± 9.67
46.7
(2.9–65.8)

48.27 ± 23.53
48.3
(22.1–432)

47.2 ± 9.82**
46.2
(2.3–79.2)

40.47 ± 8.58
40.05
(24.1–69.3)

Plt (×109/L)
mean ± SD
Median
(range)

605.91 ± 391.254**
532.5
(101–2571)

321 ± 283.87
229
(19–1697)

666.7 ± 299.117**
683.5
(44–1311)

466.72 ± 394.96
354.5
(25–2350)

Lymphocytes,
mean ± SD
Median
(range)

17.31 ± 8.64**
17
(1–42)

31.82 ± 13.72
32
(1–93)

20.24 ± 10.48**
20
(1–48)

27.73 ± 12.16
27.5
(4–60)

Neutrophils,
mean ± SD
Median
(range)

67.26 ± 13.94**
69
(6–88)

56.14 ± 13.43
56
(3–91)

67.31 ± 12.18**
65.5
(18–90)

59.32 ± 13.58
61
(6–89)

4. Discussion
It has been recently shown that the majority of patients
with PV, and substantial numbers of patients with PMF
and ET or other MPNs, carry a single nucleotide mutation
in the JAK2 gene (14–16,23–25). Since determination
of the JAK2 point mutation contributes to the diagnosis
of these diseases, elucidation of JAK2 V617F mutation
is profitable and could be helpful in therapeutic targets,
especially when particular chemotherapeutic agents are
used in the treatment of other cancers (26,27). Therefore,
in this study, the JAK2 V617F mutation was identified in
615 patients with suspected MPNs that were referred by
physicians for this mutation analysis.
In this study the JAK2 V617F mutation was identified
in all patients with PV (100%), whereas other studies

reported different results, including those of Baxter et al.
(97%) (14), James et al. (88%) (15), Levine et al. (74%)
(16), Kralovics et al. (65%) (23), Jones et al. (81%) (24),
Zhao et al. (83%) (17), and Jelinek et al. (86%) (25). The
most prevalent JAK2 mutation in PV was reported by
Baxter et al. (97%), where they used an allele-specific PCR
method, whereas the lowest reported prevalence was from
the study of Kralovics et al. (65%), in which they used
microsatellite mapping and DNA sequencing methods
for JAK2 mutation detection. Our study showed a higher
frequency of JAK2 V617F mutation in patients with PV
(100%) than that reported in the West. This difference
could be attributed to ethnic variation or the sampling
population, but it needs confirmation by further research.
In this study, patients with PV showed a higher WBC
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count (P < 0.01). This finding is consistent with previous
studies, such as that of Speletas et al. (28), which showed a
higher WBC count (P = 0.02) in patients with PV.
We have identified the JAK2 V617F mutation in
approximately 79 (45.6%) of patients with ET. Similar
studies reported different results, including those of Baxter
et al. (57%) (14), James et al. (43%) (15), Levine et al. (32%)
(16), Kralovics et al. (23%) (23), Jones et al. (41%) (24),
and Jelinek et al. (30%) (25). Campbell et al. evaluated 806
patients with ET for JAK2 mutation in 2005 (29). They
showed that 414 (53.4%) of the patients were positive for
the JAK2 mutation and 362 (46.6%) were negative. They
also reported that patients who were positive for the JAK2
mutation had a higher Hb level (P < 0.0001) and neutrophil
count (P < 0.0001) than the negative group. However, our
results did not show any statistical discrepancy in Hb level
(P > 0.1) or WBC count (P > 0.1) in the JAK2 mutation
positive group as compared to the negative group. This may
be related to the difference in the population of patients in
our study and the study of Campbell et al.
In this study, the JAK2 V617F mutation was identified
in 27 patients with PMF (39.7%); nevertheless, other
studies reported different results for this mutation in
patients with PMF, including those of Baxter et al. (50%)
(14), James et al. (43%) (15), Levine et al. (35%) (16),
Kralovics et al. (57%) (23), Jones et al. (43%) (24), Jelinek
et al. (95%) (25), and Campbell et al. (29). Recent research
has shown the diagnostic and prognostic importance of
hematological markers in various diseases (30,31). The
PMF patients with the JAK2 positive mutation have a
higher WBC and neutrophil count compared to JAK2
negative mutation patients with PMF, but platelet count,

spleen size, and Hb level did not show any difference
between JAK2-positive and -negative patients with PMF.
In our study, patients with PMF showed a higher WBC
count (P = 0.07) and Hb level (P = 0.007) in patients with
JAK2 positive mutation as compared to patients with
JAK2 negative mutation, but Plt count (P = 0.12) did not
show any difference between JAK2-positive and -negative
patients with MF. Jelinek et al. (25) used a pyrosequencing
method for JAK2 mutation analysis in patients with PMF
and reported the highest prevalence (95%), unlike Levine
et al. (16), who reported the lowest prevalence in PMF
patients with JAK2 mutation.
Briefly, this study has presented the importance of
peripheral blood mutation screening for JAK2 V617F in
the initial evaluation of patients with suspected MPNs.
JAK2 mutation analysis is a sensitive and simple test,
relatively cost-effective for proving the nature of these
diseases. It also helps in eliminating a large number of
secondary causes. However, since the mutation may be
absent in some cases of MPNs, it cannot be used as a
single test for making the diagnosis. It should be done in
addition to other hematological or biochemical tests. JAK2
mutation screening can also be used for other indications
such as unexplained erythrocythemia, thrombocytosis,
and uncommon thrombotic complications. Finally,
detection of this mutation may have an important role
in the treatment of patients who would respond to JAK2
inhibitor therapy.
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